International Stem Cell Corp. (ISCO)

[236T568]

which all fall under the R&D expense category, which was only $2.7 million of the massive $6.0 million Net Loss

If ISCO stopped all R&D, they may have losses for a period of adjustment, but their structure would change to avoid peripheral and parasitic costs that are in-part intertwined at the moment.